About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
Twitter List
Legislative Tracking Tools
Monthly Archives: April 2008
Stupak and Dingell “Concerned” May Spell Additional Reforms
On Friday, April 11, the House Committee on Energy and Commerce issued a release entitled "After Review of ENHANCE Trial Documents, Dingell, Stupak Express "Serious Concerns"" after writing to the CEOs of Merck and Schering Plough to ask for additional … Continue reading
Posted in Current Affairs, Legislation
Comments Off on Stupak and Dingell “Concerned” May Spell Additional Reforms
Weekly Roundup – 04/11/08
Well, Congress is back and writing enough letters to the stakeholders in the pharmaceutical industry to keep the Post Office in the black for many months! The cherry blossoms have peaked and we have settled into several days of gloomy … Continue reading
Posted in Weekly Roundup
1 Comment
A Signal for the Future on Intellectual Property?
Congressman Henry Waxman (D-CA), through the House Committee on Oversight and Reform, sent a letter to Susan C. Schwab, the U.S. Trade Representative yesterday that urged her to focus on access to medicines for those treatments that were life-saving weighing … Continue reading
Posted in Intellectual Property
Comments Off on A Signal for the Future on Intellectual Property?
Warning Letter Summary – First Quarter 2008
For some time, I have been writing about the lack of enforcement coming out of FDA in general and the Division of Drug Marketing and Advertising and Communications (DDMAC). Well, DDMAC has hit a new low. In looking at warning … Continue reading
Posted in Warning Letters
Comments Off on Warning Letter Summary – First Quarter 2008
More DTC Reforms
Yesterday I noted that there were letters flowing down from the Hill to manufacturers regarding some specific examples of Direct-to-Consumer (DTC) ads that were of interest to various members for various reasons. Today, the Los Angeles Times carries a report … Continue reading
Posted in DTC Advertising
Comments Off on More DTC Reforms